Lisdexamfetamine

Drug Profile

Lisdexamfetamine

Alternative Names: Elvanse; Elvanse Adult; LDX; Lisdexamfetamine dimesilate; Lisdexamfetamine dimesylate; NRP-104; S-877489; SPD-489; Tyvense; Venvanse; Vyvanse

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator New River Pharmaceuticals
  • Developer Lindner Center of HOPE; Shionogi; Shire
  • Class Amides; Amphetamines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder; Eating disorders
  • Phase II Mood disorders
  • Discontinued Bipolar depression; Cocaine abuse; Major depressive disorder; Schizophrenia; Sleep disorders

Most Recent Events

  • 28 Nov 2016 Launched for Eating disorders in Canada (PO)
  • 25 Oct 2016 Registered for Eating disorders in Canada (PO)
  • 17 Oct 2016 US FDA approves labelling change for lisdexamfetamine to include supplemental data demonstrating maintenance efficacy in adults with moderate to severe Binge eating disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top